In vitro susceptibility of sea lion poxvirus to cidofovir

被引：3

作者：

Nollens, Hendrik H. ^{[1
,2
]}

Gulland, Frances M. D. ^{[3
]}

Jacobson, Elliott R. ^{[1
,2
]}

Hernandez, Jorge A. ^{[4
]}

Klein, Paul A. ^{[5
]}

Walsh, Michael T. ^{[1
,2
]}

Condit, Richard C. ^{[6
]}

机构：

[1] Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA

[2] Univ Florida, Marine Mammal Hlth Program, Gainesville, FL 32610 USA

[3] Marine Mammal Ctr, Sausalito, CA 94965 USA

[4] Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA

[5] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA

[6] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA

来源：

ANTIVIRAL RESEARCH | 2008年 / 80卷 / 01期

关键词：

isatin-beta-thiosemicarbazone; rifampicin; acyclovir; cidofovir; phosphonoacetic acid; sea lion; seal; parapoxvirus; poxvirus; treatment;

D O I：

10.1016/j.antiviral.2008.03.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Parapoxviruses of seals and sea lions are commonly encountered pathogens with zoonotic potential. The antiviral activity of the antiviral compounds isatin-beta-thiosemicarbazone, rifampicin, acyclovir, cidofovir and phosphonoacetic acid against a parapoxvirus (SLPV-1) isolated from a Californian sea lions (Zalophus californianus) was evaluated. Cidofovir was able to reduce virus-induced cytopathic effect of SLPV-1 in confluent monolayers when used in concentrations greater than 2 mu g/ml. A decreasing virus yield was observed in the presence of increasing concentrations of cidofovir, which confirmed the ability of cidofovir to inhibit SLPV-1 replication. The in vitro efficacy of cidofovir against SLPV-1 indicates the therapeutic potential of cidofovir for the treatment of infections of humans and pinnipeds with parapoxviruses of seals and sea lions. This study confirms the previously proposed therapeutic potential of cidofovir for the treatment of parapoxvirus infections. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：77 / 80

页数：4

共 33 条

[1]

*AM SOC HOSP PHARM, 2003, AM HOSP FORM SERV DR

[2] RESISTANCE OF VACCINIA VIRUS TO RIFAMPICIN CONFERRED BY A SINGLE NUCLEOTIDE SUBSTITUTION NEAR THE PREDICTED NH2 TERMINUS OF A GENE ENCODING AN MR 62,000 POLYPEPTIDE [J].

BALDICK, CJ ;

MOSS, B .

VIROLOGY, 1987, 156 (01) :138-145

[3] Characterization of sealpox virus, a separate member of the parapoxviruses [J].

Becher, P ;

König, M ;

Müller, G ;

Siebert, U ;

Thiel, HJ .

ARCHIVES OF VIROLOGY, 2002, 147 (06) :1133-1140

[4] Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model [J].

Buller, RM ;

Owens, G ;

Schriewer, J ;

Melman, L ;

Beadle, JR ;

Hostetler, KY .

VIROLOGY, 2004, 318 (02) :474-481

[5] Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic [J].

Clark, C ;

McIntyre, PG ;

Evans, A ;

McInnes, CJ ;

Lewis-Jones, S .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (04) :791-793

[6] A VACCINIA VIRUS ISATIN-BETA-THIOSEMICARBAZONE RESISTANCE MUTATION MAPS IN THE VIRAL GENE ENCODING THE 132-KDA SUBUNIT OF RNA-POLYMERASE [J].

CONDIT, RC ;

EASTERLY, R ;

PACHA, RF ;

FATHI, Z ;

MEIS, RJ .

VIROLOGY, 1991, 185 (02) :857-861

[7] MECHANISM OF ACTION OF FOSCARNET AGAINST VIRAL POLYMERASES [J].

CRUMPACKER, CS .

AMERICAN JOURNAL OF MEDICINE, 1992, 92 :S3-S7

[8] Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir [J].

Cundy, KC .

CLINICAL PHARMACOKINETICS, 1999, 36 (02) :127-143

[9] Cidofovir in the therapy and short-term prophylaxis of poxvirus infections [J].

De Clercq, E .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (10) :456-458

[10] Cidofovir in the treatment of poxvirus infections [J].

De Clercq, E .

ANTIVIRAL RESEARCH, 2002, 55 (01) :1-13

← 1 2 3 4 →